The effect of hexose monophosphate shunt inhibitors on adenohypophyseal and ceruloplasmin reactions to oestrogen
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
151286
Knihovny.cz E-resources
- MeSH
- 6-Aminonicotinamide pharmacology MeSH
- Pituitary Gland, Anterior drug effects MeSH
- Ceruloplasmin analysis MeSH
- Estrogens administration & dosage MeSH
- Hexosephosphates antagonists & inhibitors MeSH
- Rats MeSH
- Niacinamide analogs & derivatives MeSH
- Oxythiamine pharmacology MeSH
- Thyroxine-Binding Proteins MeSH
- Thiazoles pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- 6-Aminonicotinamide MeSH
- Ceruloplasmin MeSH
- Estrogens MeSH
- Hexosephosphates MeSH
- Niacinamide MeSH
- Oxythiamine MeSH
- Thyroxine-Binding Proteins MeSH
- Thiazoles MeSH
Oestradiol benzoate, as an aqueous microcrystal suspension, was administered i.m. to rats in doses of 1 mg twice a week; it induced adenohypophyseal hyperplasia and an increase of the thyroxine-binding capacity of the adenohypophyseal proteins in vitro and raised the blood ceruloplasmin level. The simultaneous administration of a hexose monophosphate shunt inhibitor--6-aminonicotinamide (200 microgram/rat/day in food) or oxythiamine (8 mg/rat/day in food)--did not modify the reaction of the adenohypophysis; the hexose monophosphate shunt thus probably does not play a significant role in the adenohypophyseal reaction to oestrogens. By themselves, both inhibitors raised the blood ceruloplasmin level and their effect summated with that of oestradiol. The mechanism of action of the inhibitors is not known, but a nonspecific stress effect leading to an increase in the ceruloplasmin level as an "acute phase protein" is considered to be the most likely.